UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble

MT Newswires Live09-29 20:26

UniQure (QURE) said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.

The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale showed 44% slowing of disease progression in 12 high-dose patients at 48 months, lower than the updated 36-month data of 80% slowing of disease progression in 15 high-dose patients.

Total functional capacity delivered a 61% slowing of disease progression in 12 high-dose patients at 48 months, compared with the updated 36-month data of 67%, the company said.

The company's shares fell 52.5% in premarket activity Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2671348214?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2671348214","market":"sh","top_or_hot":-1,"title":"UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble","media":"MT Newswires Live","content":"<html><body><p> UniQure (QURE) said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.</p><p>The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale showed 44% slowing of disease progression in 12 high-dose patients at 48 months, lower than the updated 36-month data of 80% slowing of disease progression in 15 high-dose patients.</p><p>Total functional capacity delivered a 61% slowing of disease progression in 12 high-dose patients at 48 months, compared with the updated 36-month data of 67%, the company said.</p><p>The company's shares fell 52.5% in premarket activity Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-29 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> UniQure (QURE) said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.</p><p>The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale showed 44% slowing of disease progression in 12 high-dose patients at 48 months, lower than the updated 36-month data of 80% slowing of disease progression in 15 high-dose patients.</p><p>Total functional capacity delivered a 61% slowing of disease progression in 12 high-dose patients at 48 months, compared with the updated 36-month data of 67%, the company said.</p><p>The company's shares fell 52.5% in premarket activity Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DTRE","symbol_name":"First Trust Alerian Disruptive Technology Real Estate ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2671348214","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2671348214","pubTimestamp":1790684805,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UniQure  said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale showed 44% slowing of disease progression in 12 high-dose patients at 48 months, lower than the updated 36-month data of 80% slowing of disease progression in 15 high-dose patients.Total functional capacity delivered a 61% slowing of disease progression in 12 high-dose patients at 48 months, compared with the updated 36-month data of 67%, the company said.The company's shares fell 52.5% in premarket activity Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DTRE":"First Trust Alerian Disruptive Technology Real Estate ETF","AMT":"美国电塔","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IDGT":"ISHARES U.S. DIGITAL INFRASTRUCTURE AND REAL ESTATE ETF","BK4139":"生物科技","BK4084":"特种房地产投资信托","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","HELS":"Hedgeye 130/30 Equity ETF","AVRE":"Avantis Real Estate ETF","BYRE":"Principal Real Estate Active Opportunities ETF","TRUR":"VanEck Real Estate TruSector ETF","XLRE":"Real Estate Select Sector SPDR Fund","CRED":"COLUMBIA RESEARCH ENHANCED REAL ESTATE ETF","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","QURE":"uniQure N.V.","DFGR":"DIMENSIONAL GLOBAL REAL ESTATE ETF","DTCR":"Global X Data Center & Digital Infrastructure ETF","WTRE":"WisdomTree New Economy Real Estate Fund","SRVR":"PACER DATA & INFRASTRUCTURE REAL ESTATE ETF","VNQ":"不动产信托指数ETF-Vanguard","REAI":"The Intelligent Real Estate ETF","URE":"两倍做多房地产ETF-ProShares","ICF":"不动产指数ETF-iShares","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PSR":"Invesco Active U.S. Real Estate ETF","BK4554":"元宇宙及AR概念","FREL":"Fidelity MSCI Real Estate Index ETF","BK4581":"高盛持仓","BK4219":"电信塔房地产信托"},"translate_title":"UniQure 表示，额外的 AMT-130 数据显示 4 年后结果较弱；股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNQ":0.6,"DTRE":0.6,"DTCR":0.6,"IDGT":0.6,"REAI":0.6,"URE":0.6,"FREL":0.6,"CRED":0.6,"PSR":0.6,"ICF":0.6,"AMT":1.5,"HELS":1.5,"AVRE":0.6,"XLRE":0.6,"WTRE":0.6,"QURE":1,"SRVR":0.6,"DFGR":0.6,"TRUR":0.6,"BYRE":0.6},"content_text":"UniQure (QURE) said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale showed 44% slowing of disease progression in 12 high-dose patients at 48 months, lower than the updated 36-month data of 80% slowing of disease progression in 15 high-dose patients.Total functional capacity delivered a 61% slowing of disease progression in 12 high-dose patients at 48 months, compared with the updated 36-month data of 67%, the company said.The company's shares fell 52.5% in premarket activity Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2671348214","isCrawlerRequest":true}